Despite most of the prolactinomas can be treated with endocrine therapy and/or surgery, a
significant percentage of these tumors can be resistant to endocrine treatments and/or recur …

Objective A somatic mutational hotspot in the SF3B1 gene was reported in lactotroph
tumours. The aim of our study was to examine the prevalence of driver SF3B1 variants in a …

Purpose To describe quality and outcomes of patient-reported outcome (PRO) measures
(PROMs) used in patients with refractory hormone-producing pituitary adenomas, and to …

Purpose Refractory prolactinomas resistant to dopamine agonists (DAs) pose a clinical
challenge. Temozolomide (TMZ) is a recommended treatment option, but its effects are …

Objective: Prolactinomas are the most common type of functional, hormone-secreting
pituitary adenomas that account for about 40% of total pituitary adenomas. Typical clinical …

The recent Consensus Statement on the diagnosis and management of prolactin-secreting
pituitary adenomas (prolactinomas) drew attention to molecular pathogenetic mechanisms …

Introduction Pituitary adenomas can show a tendency to grow, despite multimodal treatment.
Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary …

We read with great interest the article by Zielinski et al.(1) reporting indicators for early
remission (ie, 3 months) after transsphenoidal surgery in 48 prolactinoma patients resistant …

Objective The management of refractory pituitary adenomas (RPAs) presents significant
challenges. This study aimed to evaluate the long-term treatment outcomes of patients with …

Purpose Refractory prolactinomas resistant to dopamine agonists (DAs) pose a clinical
challenge. Temozolomide (TMZ) is a recommended treatment option, but its effects are …